ACRP and CenterWatch released a collaborative benchmarking report on clinical research site performance.
The Association of Clinical Research Professionals (ACRP), one of the largest representative organizations for clinical research professionals in the world, and CenterWatch, the leading source for clinical trials information, today released a collaborative benchmarking report on clinical research site performance as a result of the largest independent, unbiased survey of site leadership.
Among highlights of the data:
The survey data is available in two separate reports, one comparing smaller study sites to average site metrics, and another comparing larger study sites to the average, providing a greater degree of relevance to the site market.
This unique market research provides benchmarking metrics on:
"We are proud to provide the largest component of our membership, site personnel, with the data they need to most effectively run their businesses," says James Thomasell, ACRP Executive Director. "And we are thrilled to be able to do so through our collaborative partnership with CenterWatch. There is no better team to provide the kind of robust and trustworthy data needed to drive decision making at the site level."
"We are pleased to be collaborating with ACRP on this survey to provide industry professionals with insightful and analytical information on the business operations of the investigative site and how it is evolving," says Joan Chambers, COO, CenterWatch. "We are looking forward to conducting more surveys with ACRP and providing benchmarking reports as part of our collaborative partnership."
The data is available at www.acrpnet.org/sitebenchmarking and http://store.centerwatch.com/p-433-2014-financial-and-operating-benchmark-reports.aspx
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.